Workflow Efficiency Solutions for R&D-Driven Organizations

Corporate Presentation – February 2020

2

This presentation contains forward-looking statements that relate to future activities, events or

developments. All statements, other than statements of fact, that address activities, events or

developments that the company or its management expect, project, believe or anticipate will or may

occur in the future, or that relate to historical periods that will be reported in future filings with the

Securities and Exchange Commission, are forward-looking statements. Forward-looking statements are

made based on management’s assumptions and assessments in light of past experience and trends,

current conditions, expected future developments and other relevant factors. Forward-looking

statements are not guarantees of performance, and actual results, developments and business

decisions may differ from those envisaged by these forward-looking statements. These forward-looking

statements are also subject to risks and uncertainties which can affect the company’s performance in

both the near-and long-term. The company identifies many of these risks and uncertainties that could

affect its performance in its SEC filings, including its most recent reports on Form 10-K and Form 10-Q,

particularly under the heading "Risk Factors." Copies of these filings are available online from the SEC or

at the company’s website. The company undertakes no duty to update any statement in light of new

information or future events, or for any other reason.

© 2020 Research Solutions, Inc. – All Rights Reserved

Forward Looking Statements

3

The Bloomberg or Lexis Nexis for Scientific, Technical & Medical Research

SCIENTIFIC RESEARCH

Articles from Scientific, Technical

& Medical (STM) Journals, R&D Efficiency Tools

Laws, Legal Cases & Opinions

Annual Reports & Financial Market Data

FINANCIAL RESEARCH LEGAL RESEARCH

4

The Research Process is Broken

Researchers Overloaded by

Information & Poor Filtering Tools

----------------------- Drowning users in millions of newly

published research papers, patents, books

& reports

Key Information Locked Behind

Copyright & Online Paywalls

----------------------- Forcing users to visit

multiple online websites to legally

check access, view or purchase content

Once Unlocked, Data Extraction is Manual & Labor-

Intensive ----------------------

Requiring significant amounts

of human resources, reviews & documentation

Slowing Down Discovery in the Race to Create

Intellectual Property ----------------------- Putting IP pipelines & corporate survival

at risk

5

Research Solutions At-a-Glance

Research Solutions provides workflow efficiency solutions for R&D-driven organizations in life sciences, technology & academia worldwide

We generate revenue from a fast-growing subscription-based SaaS platform business & a transaction business

Our all-in-one SaaS platform provides tools or “Gadgets” that allow users to discover, access, manage & collaborate around science, technology & medical (STM) content & data

Our customers include…

70+% of the top 25 pharma companies

Small/medium-sized businesses (SMB) focused on research

Academic institutions

Our platforms focus is driving strong recurring revenue & gross margin ~4x that of our transaction business (or ~80%)

6

Our Strategic Evolution is Underway

We Are Evolving into a More Profitable, Higher Growth Company via Platforms

PLATFORMS

Subscription-based SaaS revenue model

Higher margin (~80%)

No direct substitute

Low churn

Trailing 12-month gross margin = 82.4%

TRANSACTIONS

Transactional revenue model

Sticky, repeat revenue

Service 70%+ of top 25 pharma companies

Trailing 12-month gross margin = 23.4%

7

Platform & Transaction Revenue Model¹ PLATFORMS

Annual platform subscription fee, recurring & predictable

Annual recurring revenue (ARR)1 = ~$3.7M

Average selling price (ASP) = ~$11K

TTM gross margin = 82.4%

TRANSACTIONS

Sticky & repeat revenue

TTM gross margin = 23.4%

1) Annual recurring revenue & average revenue per transaction are defined on page 25.

$24.3M $24.3M $24.8M

$25.1M

$25.7M $26.1M $26.2M $26.2M $26.1M $26.0M $26.0M

$26.4M $26.6M

774K 789K

810K 824K 835K 842K 843K 840K 838K 830K 831K 845K 855K

Transaction Revenue/Count

TTM Revenue TTM Transaction Count

$0.9M $1.1M

$1.4M $1.6M

$1.7M

$2.0M

$2.3M $2.5M

$2.7M

$3.0M

$3.2M

$3.5M $3.7M

96 116

140 161

184 208

227 239

267 281

301 320

338

Platform Annual Recurring Revenue &

Deployments¹

Annual Recurring Revenue Cumulative Deployments

8

Our Platform Features Single enterprise SaaS platform

Secure authentication, simplified workflows & 24/7 expert human support (no internal IT resources required)

Fastest one-stop-shop for 24/7 access to the universe of scientific & technical content

Superior tools & filters for curating & connecting disparate information, powered by a library of gadgets to extract information & fast-track knowledge creation

Replaces redundant systems, manual processes & inefficient spending with single solution featuring powerful spend management controls, automated cost avoidance features & need-based spending

Automated copyright clearance makes it easy for users to legally access & share info

9

Pricing Plans

10

Deployable across all sized organizations

Especially valued by underserved SMB market (<500 employees)

Why?

No access to existing corporate libraries, an information manager, etc.

Platforms “democratizes” these capabilities into one offering

Grounded in the rigorous requirements of our large pharmaceutical customers

~700,000 worldwide organizations have some component of R&D in their business – most are SMBs

1) Market estimates based on management estimates. 2) Assumes roughly 700,000 SMBs & a $10,000 platform cost.

~$7B Platform Market2

~4% RSSS penetration (same as our ~4% single article market penetration) would equate to ~$280M in annual

recurring revenue

~699,000 = Incremental SMB Market

RSSS Penetration =

~350 organizations (<1% of the

market)

Platform Market

Our Transaction Business Enjoys a Large Addressable Market

11

70M+ scientific, technical & medical articles worldwide

1.7M+ new articles published each year

We have ~4% market share in the single article market today (i.e. our Transactions business)

We believe overall market well-positioned for academic & corporate clients as they embrace single article model

1) Market estimates based on management analysis of historical Outsell data and other sources, and excludes academic subscription market.

20162017E

2018E2019E

2020E

$3.2 $3.3

$3.4 $3.5

$3.7

$0.73 $0.76 $0.79 $0.82 $0.85

~$4B Total Addressable Market1

Corporate Subscription Market Single Article Market

$3.9B $4.1B $4.2B

$4.3B $4.6B

12

Loyal, Marquee Customer Base

Stable & growing base of 338+ platform customers & 1,100+ transaction customers

~$3.7M in ARR from platform subscriptions

Virtually zero top customer churn

Revenue concentrations

Top customer: ~4% of revenue

Top 10 customers: ~25% of revenue

Top 35 customers: ~50% of revenue

13

We are Partnered with Leading & Long-Established Publishers

Long-Term Growth Drivers

14

Underserved SMB Market

Efficient Sales &

Marketing

International Penetration

Upsell Transaction Customers

700,000 SMBs (<1% penetration)

Fewer information resources for SMBs driving greater willingness to procure our services & faster close rates

International sales represent ~50% of our business today (only ~25% for Platforms)

Replicate successful U.S. playbook to grow in these large markets

Identify and focus on key partnerships for great market penetration.

Upsell transaction customers onto the platform

Upsell platform customers at annual renewal

Recruiting new customers via focused prospecting, content-driven marketing, SEO & SEM, and effective appointment setting for product demos and value proposition discussions

Retaining & upselling existing customers for maximum share of wallet

15

Financial Overview

Key Stats

16

Percentage of Outstanding Shares Stock Price (2/12/20) $3.50

52 Week Low-High $1.90-$4.00

Avg. Daily Vol. (30d) 2,035

Shares Out/Diluted 24.5M/29.8M

Float (est.) ~3.0M

Insider Holdings ~70%

Enterprise Value $79.2M

Market Cap $86.0M

Employee Count

(including full time

contractors)

148 Total

29 USA/108 MX

11 Contractors

(ttm) = trailing twelve months as of Dec. 31, 2019 (mrq) = most recent quarter as of Dec. 31, 2019 NOTE: On February 19 and 20, 2020, certain holders of warrants to purchase shares of our common stock at a per share exercise price of $1.25 exercised warrants to purchase 1,500,000 shares, generating gross proceeds of $1,875,000. See page 26 for a pro-forma balance sheet.

Total Revenue (ttm) $30.0M

Net Income (ttm) $(0.9)M

EPS (ttm) $(0.04)

EV/Revenue 2.6x

Cash and Equiv. (mrq) $6.8M

Total Assets (mrq) $11.7M

Total Debt (mrq) $0.0M

Total Liabilities (mrq) $8.9M

Total Equity $2.8M Total 100.0 %

12 West Capital 24.9%

Bristol Inv. Fund, Ltd. 19.7%

Peter Derycz 15.1%

Employees/Directors 9.0%

Samjo/Haff Partners 5.4%

Richard Witmer 4.9%

Other ~21.0%

Revenue Profile

17

Platforms: Fastest-growing and recurring No direct substitute Low churn TTM gross margin 82.4%

Transactions: Sticky, scalable, repeat revenue TTM gross margin 23.4%

$18.5M $21.2M

$23.7M $24.8M $26.2M [VALUE]M [VALUE]M

FY14 FY15 FY16 FY17 FY18 FY19 TTM

12/31/19

$0.1M $0.2M $0.4M

$1.0M

$1.8M

[VALUE]M

[VALUE]M

FY14 FY15 FY16 FY17 FY18 FY19 TTM

12/31/19

Total Revenue $18.7M

Total Revenue $21.4M

Total Revenue $24.1M

Total Revenue $25.8M

Total Revenue $28.0M

Total Revenue $28.8M

Total

Revenue $30.0M

Balance Sheet Supports Growth

$6.8 million in cash

$0 debt

Untapped $2.5 million max line of credit

Prime plus 2.25%¹

Federal net operating losses (NOLs) of ~$14 million, state NOLs of ~$7 million

NOLs expire completely in 2039

We are fully funded to execute our growth strategy

18

Select Balance Sheet Items

$ Millions Dec 31,

2019

Jun 30,

2019

Cash and equivalents 6.8 5.4

Accounts receivable 4.2 4.5

Prepaid expenses/royalties 0.3 0.3

Other assets 0.4 0.2

Total Assets $11.7 $10.4

Accounts payable 5.9 4.9

Deferred revenue 2.9 2.3

Lease liability 0.1 0.2

Total Liabilities $8.9 $7.4

Total Stockholders' Equity $2.8 $3.0 1) Only in periods in which RSSS maintains an adjusted quick ratio of

1.3 to 1.0. Prime rate plus 5.25% when not in effect.

NOTE: On February 19 and 20, 2020, certain holders of warrants to purchase shares of our common stock at a per share exercise price of $1.25 exercised warrants to purchase 1,500,000 shares, generating gross proceeds of $1,875,000. See page 26 for a pro-forma balance sheet.

Key Takeaways

Strategic SaaS Transformation Underway: platform interconnects & extracts highly useful scientific, technical & medical content & data

Information Logistics Backbone: transaction business provides multi-million dollar information backbone for platform growth

Large, Underserved Market:~700,000 SMBs throughout the world, low penetration

Highly Leveragable Financial Model: platforms business drives recurring revenue, low churn, ~80% gross margin

19

$0.9M $1.1M

$1.4M $1.6M $1.7M

$2.0M $2.3M

$2.5M $2.7M

$3.0M $3.2M

$3.5M $3.7M

96 116

140 161

184 208

227 239 267 281

301 320

338

Platform Transition Underway

Annual Recurring Revenue

Cumulative Deployments

$24.3M $24.3M $24.8M $25.1M

$25.7M $26.1M $26.2M $26.2M $26.1M $26.0M $26.0M $26.4M $26.6M

774K 789K 810K 824K 835K 842K 843K 840K 838K 830K 831K 845K 855K

Stable Transaction Business Continues

TTM Revenue TTM Transaction Count

20

Contact Us

Peter Derycz, Chairman & CEO Alan Urban, CFO

Research Solutions, Inc. 16350 Ventura Blvd., Suite D #811 Encino, California 91436 ir@researchsolutions.com For more information, please visit: www.researchsolutions.com

Investor Relations Contact:

Cody Slach Gateway Investor Relations 949-574-3860 • RSSS@gatewayir.com

21

Appendix

Leadership Team

22

PETER DERYCZ

CEO

• Founded Research Solutions in 2006

• Founded then sold Infotrieve Inc. to private equity investors in 2003

• Voted one of the 100 most influential people in Pharma by PharmaVoice

• Holder of 9 patents

• BA from UCLA

ALAN URBAN

CFO

• Previously CFO of ReachLocal (RLOC), an internet marketing company that ranked #1 on Deloitte’s Tech Fast 500

• Served as VP, Finance at Infotrieve

• 20+ years experience, Certified Public Accountant

• BS Accounting from California State University, Northridge

SCOTT AHLBERG

COO

• Three decades of information industry experience

• Previously VP of Operations at Infotrieve

• Expertise in strategic planning, operational innovation, copyright, content licensing & quality management

• MA from University of London & a BA from Stanford University

MARC NISSAN

CTO

• 20+ years of experience in systems architecture, transaction management system design, software development & technology build-out.

• Previous technology positions at Infotrieve, Ultralink, MPDN

ROGIER van ERKEL

CSO

• Previously Sales Director at Elsevier, the largest publisher of STM content

• Expertise in information products, discovery tools & solutions to optimize & maximize customer workflow

• Degree from the University of Amsterdam, BA Business Economics Hanze University of Applied Sciences Groningen

YOHANN GEORGEL

CMO

• Previously Senior Director of Digital Marketing for PrimeSport & Director of Digital Marketing for soccer fan social media platform OleOle

• Expertise in search engine optimization & marketing, data analysis, social media & user experience

Capitalization Table

23

SECURITY AS OF

DEC 31, 2019 WEIGHTED AVERAGE

EXERCISE PRICE PERCENTAGE

FULLY DILUTED

Common Stock Outstanding 24,475,556 N/A 82.2%

Stock Options 3,416,580 $1.53 11.5%

Warrants 1,885,000 $1.25 6.3%

Fully Diluted Shares Outstanding 29,777,136 100.0%

MAJOR SHAREHOLDERS AS OF

DEC 31, 2019 SECURITY

PERCENTAGE OF COMMON STOCK OUTSTANDING

12 West Capital 6,091,000 Common Stock 24.9%

Bristol Investment Fund, Ltd.1 4,825,772 Common Stock 19.7%

Peter Derycz, CEO 3,695,594 Common Stock 15.1%

Samjo Capital 1,323,482 Common Stock 5.4%

Richard Witmer, Jr. 1,208,448 Common Stock 4.9%

Management, Directors & Employees 2,201,407 Common Stock 9.0%

Total 19,345,703 79.0%

1) Paul Kessler exercises investment & voting control over the shares held by Bristol Investment Fund, Ltd. and is the brother-in-law of Peter Derycz, CEO.

Quarterly Financial Results

24

Quarterly Financial Results

25

NASDAQ Uplisting / Pro-Forma Balance Sheet

26

On February 19 and 20, 2020, certain

holders of warrants to purchase shares of our

common stock at a per share exercise price of

$1.25 exercised warrants to purchase 1,500,000

shares, generating gross proceeds of $1,875,000.

The following table sets forth our unaudited

condensed consolidated balance sheet as of

December 31, 2019 on an as reported basis and

on an unaudited pro-forma basis giving effect to

the warrant exercise.

The following table reflects an unaudited

pro-forma total stockholders’ equity of $4,697,991,

in reference to the stockholders’ equity criterion of

the market value of listed securities standard of

The Nasdaq Capital Market, which requires

stockholders’ equity of $4,000,000. While we

intend to pursue a listing of our common stock on

The Nasdaq Capital Market, acceptance for such

listing is subject to approval, in part, based on our

ability to meet all of the listing requirements for

The Nasdaq Capital Market.

We intend to satisfy all of such applicable

listing criteria, but can provide no assurance that

The Nasdaq Stock Market LLC will approve our

application for listing.

27

Platform Features Comparison